Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

31 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Rapid disease progression following discontinuation of ibrutinib in patients with chronic lymphocytic leukemia treated in routine clinical practice.
Hampel PJ, Ding W, Call TG, Rabe KG, Kenderian SS, Witzig TE, Muchtar E, Leis JF, Chanan-Khan AA, Koehler AB, Fonder AL, Schwager SM, Slager SL, Shanafelt TD, Kay NE, Parikh SA. Hampel PJ, et al. Leuk Lymphoma. 2019 Nov;60(11):2712-2719. doi: 10.1080/10428194.2019.1602268. Epub 2019 Apr 24. Leuk Lymphoma. 2019. PMID: 31014142 Free PMC article.
Addition of venetoclax at time of progression in ibrutinib-treated patients with chronic lymphocytic leukemia: Combination therapy to prevent ibrutinib flare.
Hampel PJ, Call TG, Ding W, Muchtar E, Kenderian SS, Wang Y, Leis JF, Witzig TE, Koehler AB, Fonder AL, Schwager SM, Rabe KG, Van Dyke DL, Braggio E, Slager SL, Kay NE, Parikh SA. Hampel PJ, et al. Am J Hematol. 2020 Mar;95(3):E57-E60. doi: 10.1002/ajh.25690. Epub 2019 Dec 13. Am J Hematol. 2020. PMID: 31788844 Free article. No abstract available.
Incidence and risk of tumor lysis syndrome in patients with relapsed chronic lymphocytic leukemia (CLL) treated with venetoclax in routine clinical practice.
Koehler AB, Leung N, Call TG, Rabe KG, Achenbach SJ, Ding W, Kenderian SS, Leis JF, Wang Y, Muchtar E, Hayman SR, Hampel PJ, Finnes HD, Schwager SM, Slager SL, Kay NE, Parikh SA. Koehler AB, et al. Among authors: hampel pj. Leuk Lymphoma. 2020 Oct;61(10):2383-2388. doi: 10.1080/10428194.2020.1768384. Epub 2020 May 25. Leuk Lymphoma. 2020. PMID: 32449401
The significance of gradient expression of chromosome region maintenance protein 1 (exportin1) in large cell lymphoma.
Abeykoon JP, Hampel PJ, King RL, Wood AJ, Larson MC, Nowakowski KE, Zanwar SS, Dasari S, Ruan GJ, Ravindran A, Wellik LE, Paludo J, Link BK, Cerhan JR, Ansell SM, Nowakowski GS, Thompson CA, Maurer MJ, Wenzl K, Novak AJ, Wu X, Habermann TM, Witzig TE. Abeykoon JP, et al. Among authors: hampel pj. Haematologica. 2021 Aug 1;106(8):2261-2264. doi: 10.3324/haematol.2020.278277. Haematologica. 2021. PMID: 33657788 Free PMC article. No abstract available.
Immune-related hematologic adverse events in the context of immune checkpoint inhibitor therapy.
Saliba AN, Xie Z, Higgins AS, Andrade-Gonzalez XA, Fuentes-Bayne HE, Hampel PJ, Kankeu Fonkoua LA, Childs DS, Rakshit S, Bezerra ED, Kommalapati A, Lou Y, Rivera CE, Price KA, Chintakuntlawar A, Yan Y, Schwecke AJ, Block MS, Thanarajasingam U, Thanarajasingam G, Wolanskyj-Spinner AP, Marshall AL, Kottschade LA, Go RS, Al-Kali A. Saliba AN, et al. Among authors: hampel pj. Am J Hematol. 2021 Oct 1;96(10):E362-E367. doi: 10.1002/ajh.26273. Epub 2021 Jul 2. Am J Hematol. 2021. PMID: 34137072 Free article. No abstract available.
Artificial Intelligence Electrocardiography to Predict Atrial Fibrillation in Patients With Chronic Lymphocytic Leukemia.
Christopoulos G, Attia ZI, Achenbach SJ, Rabe KG, Call TG, Ding W, Leis JF, Muchtar E, Kenderian SS, Wang Y, Hampel PJ, Koehler AB, Kay NE, Kapoor P, Slager SL, Shanafelt TD, Noseworthy PA, Friedman PA, Herrmann J, Parikh SA. Christopoulos G, et al. Among authors: hampel pj. JACC CardioOncol. 2024 Apr 16;6(2):251-263. doi: 10.1016/j.jaccao.2024.02.006. eCollection 2024 Apr. JACC CardioOncol. 2024. PMID: 38774001 Free PMC article.
Venetoclax treatment of patients with relapsed T-cell prolymphocytic leukemia.
Hampel PJ, Parikh SA, Call TG, Shah MV, Bennani NN, Al-Kali A, Rabe KG, Wang Y, Muchtar E, Leis JF, Kenderian SS, Koehler AB, Schwager SM, Slager SL, Kay NE, Hanson CA, Van Dyke DL, Shi M, Ding W. Hampel PJ, et al. Blood Cancer J. 2021 Mar 2;11(3):47. doi: 10.1038/s41408-021-00443-1. Blood Cancer J. 2021. PMID: 33654067 Free PMC article. No abstract available.
31 results